Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.59 |
| ▸ | NPY1R | P25929 | 8/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.59 |
| ▸ | NPY2R | P49146 | 4/20 | 0.59 |
| ▸ | BACE1 | P56817 | 8/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31233596 | 0.94 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL8813021 | 0.92 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL8815384 | 0.92 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL30658559 | 0.92 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL30331385 | 0.91 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL29649769 | 0.91 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29649727 | 0.91 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29486226 | 0.90 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL29531768 | 0.89 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL19345805 | 0.88 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2RBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | disclosed |
| US-20250064792-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240216353-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-07-04 | — | — | US | disclosed |
| US-11918570-B2 | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230127290-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | SERPINB1, ELANE, CELA1 | NPY4R 3094/4885NPY1R 3825/4885NPY5R 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.